NPCE Key Statistics, Chart & Performance
The current stock price of NPCE is 16.36 USD. In the past month the price increased by 65.92%. In the past year, price increased by 54.34%.
NPCE Latest News, Press Relases and Analysis
NPCE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.83 | 224.14B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.61 | 203.30B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.43 | 150.59B | ||
| SYK | STRYKER CORP | 28.18 | 141.95B | ||
| IDXX | IDEXX LABORATORIES INC | 59.7 | 60.12B | ||
| BDX | BECTON DICKINSON AND CO | 13.45 | 55.61B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.72 | 50.29B | ||
| RMD | RESMED INC | 25.84 | 37.34B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.43 | 36.44B | ||
| DXCM | DEXCOM INC | 34.12 | 24.75B | ||
| PODD | INSULET CORP | 71.6 | 23.02B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 12.05 | 19.33B |
Related stock screener links
About NPCE
Company Profile
NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California and currently employs 209 full-time employees. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The firm has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
Company Info
NEUROPACE INC
455 N. Bernardo Avenue
Mountain View CALIFORNIA US
CEO: Michael Favet
Employees: 209
Phone: 16502372700
NEUROPACE INC / NPCE FAQ
Can you describe the business of NEUROPACE INC?
NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California and currently employs 209 full-time employees. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The firm has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
Can you provide the latest stock price for NEUROPACE INC?
The current stock price of NPCE is 16.36 USD. The price decreased by -0.85% in the last trading session.
What is the dividend status of NEUROPACE INC?
NPCE does not pay a dividend.
How is the ChartMill rating for NEUROPACE INC?
NPCE has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of NPCE stock?
NEUROPACE INC (NPCE) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Is NEUROPACE INC (NPCE) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NPCE.
Can you provide the ownership details for NPCE stock?
You can find the ownership structure of NEUROPACE INC (NPCE) on the Ownership tab.
NPCE Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to NPCE. When comparing the yearly performance of all stocks, NPCE is one of the better performing stocks in the market, outperforming 94.94% of all stocks.
NPCE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NPCE. NPCE may be in some trouble as it scores bad on both profitability and health.
NPCE Financial Highlights
Over the last trailing twelve months NPCE reported a non-GAAP Earnings per Share(EPS) of -0.76. The EPS increased by 24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.36% | ||
| ROE | -129.53% | ||
| Debt/Equity | 3.17 |
NPCE Forecast & Estimates
14 analysts have analysed NPCE and the average price target is 17.85 USD. This implies a price increase of 9.11% is expected in the next year compared to the current price of 16.36.
For the next year, analysts expect an EPS growth of 8.47% and a revenue growth 20.22% for NPCE